Hepatitis B virus surface antigen and polymerase gene variants: Potential virological and clinical significance
1998; Lippincott Williams & Wilkins; Volume: 27; Issue: 1 Linguagem: Inglês
10.1002/hep.510270144
ISSN1527-3350
Autores Tópico(s)HIV Research and Treatment
ResumoHepatologyVolume 27, Issue 1 p. 294-297 EditorialFree Access Hepatitis B virus surface antigen and polymerase gene variants: Potential virological and clinical significance Stephen A. Locarnini M.D., Ph.D., M.D., Ph.D., Corresponding Author Stephen A. Locarnini M.D., Ph.D., M.D., Ph.D. Head Research and Molecular Development, Victorian Infectious Diseases Reference Laboratory, Fairfield, Victoria, AustraliaResearch and Molecular Development, Victorian Infectious Diseases Laboratory, Fairfield, Victoria 3078, Australia. Fax: 61-3-9481-3816===Search for more papers by this author Stephen A. Locarnini M.D., Ph.D., M.D., Ph.D., Corresponding Author Stephen A. Locarnini M.D., Ph.D., M.D., Ph.D. Head Research and Molecular Development, Victorian Infectious Diseases Reference Laboratory, Fairfield, Victoria, AustraliaResearch and Molecular Development, Victorian Infectious Diseases Laboratory, Fairfield, Victoria 3078, Australia. Fax: 61-3-9481-3816===Search for more papers by this author First published: 30 December 2003 https://doi.org/10.1002/hep.510270144Citations: 73AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL REFERENCES 1 Kane MA. Global status of hepatitis B immunisation. Lancet 1196; 348: 696. 2 Lok ASF. Natural history and control of perinatally acquired hepatitis B virus infection. Dig Dis Sci 1992; 10: 46– 52. 3 Hadziyannis SJ. Hepatitis B e antigen negative chronic hepatitis B: from clinical recognition to pathogenesis and treatment. Viral Hep Rev 1995; 1: 7– 36. 4 Hoofnagle JH, Di Bisceglie AM. Drug Therapy: the treatment of chronic viral hepatitis. N Engl J Med 1997; 336: 347– 356.MEDLINE 5 Carman WF. The clinical significance of surface antigen variants of hepatitis B virus. J Viral Hep 1997; 4(suppl: 11– 20. 6 Bartholomeusz A, Locarnini S. Mutations in the hepatitis B virus polymerase gene that are associated with resistance to famciclovir and lamivudine. Int Antiviral News 1997; 5: 123– 124. 7 Wallace LA, Carman WF. Surface gene variation of HBV: Scientific and medical relevance. Viral Hep Rev 1997; 3: 5– 16. 8 Summers J, Mason W. Replication of the genome of a hepatitis B-like virus by reverse transcription of an RNA intermediate. Cell 1982; 9: 403– 415. 9 Mason WS, Taylor JM, Hull R. Retroid virus genome replication. Adv Virus Res 1987; 32: 35– 96.MEDLINE 10 Wang GH, Seeger C. Novel mechanism for reverse transcription in hepatitis B viruses. J Virol 1993; 67: 6507– 6512.MEDLINE 11 Girones R, Miller RH. Mutation rate of the hepadnavirus genome. Virology 1989; 170: 595– 597.MEDLINE 12 Tiollais P, Pourcel C, Dejean A. The hepatitis B virus. Nature 1985; 317: 489– 495.MEDLINE 13 Bartholomeusz A, Schinazi R, Locarnini S. Pathogenesis and significance of mutations in the hepatitis B virus polymerase selected by nucleoside analogue therapy. Viral Hep Rev 1997;in press. 14 Protzer-Knolle U, Naumann U, Berg T, Bartenschlager R, Hopf U, Meyer zum Buschenfelde K-H, Neuhaus P, et al. Hepatitis B virus with antigenically altered HBsAg is selected by high-dose hepatitis B immuneglobulin after liver transplantation. Hepatology 1998; 27: 254– 263.MEDLINE 15 Ghany MG, Ayola B, Villamil FG, Gish RG, Rojter S, Vierling JM, Lok ASF. Hepatitis B virus S mutants in liver transplant recipients who were reinfected despite hepatitis B immune globulin prophylaxis. Hepatology 1998; 27: 213– 222.MEDLINE 16 Carman WF, Zanetti AR, Karayiannis P, Waters J, Manzillo G, Tanzi E, Zuckerman AJ, thomas HC. Vaccine-induced escape mutant of hepatitis B virus. Lancet 1990; 336: 325– 329.MEDLINE 17 Ling R, Mutimer D, Ahmed M, Boxall EH, Elias E, Dusheiko GM, Harrison TJ. Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine. Hepatology 1996; 24: 711– 713.MEDLINE 18 Aye TT, Bartholomeusz A, Shaw T, Bowden S, Breschkin A, McMillan J, Angus P, et al. Hepatitis B virus polymerase mutations during antiviral therapy in a patient following liver transplantation. J Hepatol 1997; 26: 1148– 1153.MEDLINE 19 Toh H, Hayashida H, Miyata T. Sequence homology between retroviral reverse transcriptase and putative polymerases of hepatitis B virus and cauliflower mosaic virus. Nature 1983; 305: 827– 829.MEDLINE 20 Larder BA, Kemp SD, Purifoy DJ. Infectious potential of human immunodeficiency virus type 1 reverse transcriptase mutants with altered inhibitor sensitivity. Proc Natl Acad Sci U S A 1989; 86: 4803– 4807.MEDLINE 21 Kohlstaedt LA, Wang J, Friedman JM, Rice PA, Steitz TA. Crystal structure at 3.5 A resolution of HIV-1 reverse transcriptase complexed with an inhibitor. Science 1992; 256: 1783– 1790.MEDLINE 22 Schinazi RF, Lloyd RM, Nguyen MH, Cannon DL, McMillan A, Ilksov N, Chu CK, et al. Characterization of human immunodeficiency viruses resistant to oxathiolane-cytosine nucleosides. Antimicrob Agents Chemother 1993; 37: 875– 881.MEDLINE 23 Wainberg MA, Salomon H, Gu Z, Montaner JS, Cooley TP, McCaffrey R, Ruedy J, et al. Development of HIV-1 resistance to (-)2'-deoxy-3'-thiacytidine in patients with AIDS or advanced AIDS-related complex. AIDS 1995; 9: 351– 357.MEDLINE 24 Stirk HJ, Thornton JM, Howard CR. A topological model for hepatitis B surface antigen. Intervirology 1992; 33: 148– 158.MEDLINE 25 Bartholomew MM, Jansen RW, Jeffers LJ, Reddy KR, Johnson LC, Bunzendahl H, Condreay LD, et al. Hepatitis B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation. Lancet 1997; 349: 20– 22.MEDLINE 26 Tillman HL, Trautwein C, Kruger M, Boker K, Schlitt HJ, Condreay L, Deslauriars M, et al. Inhibition of hepatitis B virus replication with lamivudine in patients previously treated with famciclovir after liver transplantation [Abstract]. J Hepatol 26(suppl): 153. 27 Bartholomeusz A, Groenen LC, Locarnini SA. Clinical experience with famciclovir against hepatitis B virus and development of resistance. Intervirology 1997;in press. 28 Hsu H-Y, Chang M-H, Ni Y-H, Lin H-H, Wang S-M, Chen D-S. Surface gene mutants of hepatitis B virus in infants who develop acute or chronic infections despite immunoprophylaxis. Hepatology 1997; 26: 786– 791.MEDLINE 29 De Man RA, Bartholomeusz A, Locarnini S, Niesters HGM, Zondervan PE. The occurrence of sequential viral mutations in a liver transplant recipient re-infected with hepatitis B: primary famciclovir resistance followed by a lethal hepatitis during acquired lamivudine resistance [Abstract]. J Hepatol 1997; 26(suppl: 77. 30 Perillo R, Rakela J, Martin P, Wright T, Levy G, Schiff E, Dienstag J, et al. Lamivudine for suppression and/or prevention of hepatitis B when given pre/post liver transplantation (OLT) [Abstract]. Hepatology 1997; 26 (suppl): 260A. 31 Corey L, Holmes KK. Therapy for human immunodeficiency virus infection. What have we learned? N Engl J Med 1996; 335: 1142– 1144.MEDLINE 32 Larder BA, Kemp SD, Harrigan PR. Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy. Science 1995; 269: 696– 699.MEDLINE 33 Colledge D, Locarnini S, Shaw T. Synergistic inhibition of hepadnaviral replication by lamivudine in combination with penciclovir in vitro. Hepatology 1997; 26: 216– 225.MEDLINE 34 Locarnini SA, Aye TT, Shaw T, De Man R, Angus PW, McCaughan GW, Bartholomeusz AI. The emergence of famciclovir resistant mutations in the hepatitis B virus polymerase during therapy in patients following liver transplantation [Abstract]. Hepatology 1997; 26(suppl: 368A. 35 Condra JH, Schleif WA, Blahy OM, Gabryelski LJ, Graham DJ, Qunitero JC, Rhodes A, et al. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature 1995; 374: 569– 571.MEDLINE 36 Condra JH, Holder DJ, Schleif WA, Blahy OM, Danovich RM, Gabryelski LJ, Graham DJ, et al. Genetic correlates of in vivo viral resistance to Indinavir, a human immunodeficiency virus type 1 protease inhibitor. J Virol 1996; 70: 8270– 8276.MEDLINE 37 Condra JH, Emmini EA. Preventing HIV-1 drug resistance. Science Med 1997; 4: 2– 11. 38 de Jong MC, Boucher CAB, Galasso GJ, Hirsch MS, Kern ER, Lange JMA, Richman DD. Consensus symposium on combined antiviral therapy. Antiviral Res 1995; 129: 5– 29. Citing Literature Volume27, Issue1January 1998Pages 294-297 ReferencesRelatedInformation
Referência(s)